Kubota Pharmaceutical Holdings Co., Ltd.
Tokyo Stock Exchange 4596.T
Kubota Pharmaceutical Holdings Co., Ltd. EBT Margin for the year ending December 31, 2023: -3,734.56%
Kubota Pharmaceutical Holdings Co., Ltd. EBT Margin is -3,734.56% for the year ending December 31, 2023, a 84.71% change year over year. EBT Ratio (Earnings Before Tax Ratio) is the fraction of earnings before taxes to total revenue, indicating the company's profitability before the impact of tax expenses.
-
Kubota Pharmaceutical Holdings Co., Ltd. EBT Margin for the year ending December 31, 2022 was -24,423.38%.
-
Kubota Pharmaceutical Holdings Co., Ltd. EBT Margin for the year ending December 31, 2020 was -6,450.60%.
Key data
| Date | EBT Margin | Net Income Margin | EBITDA Margin | EBIT Margin |
|---|
Market news
Loading...
Tokyo Stock Exchange: 4596.T
| CEO | Dr. Ryo Kubota M.D., Ph.D. |
| IPO Date | Dec. 6, 2016 |
| Location | Japan |
| Headquarters | 3-7-1 Kasumigaseki |
| Employees | 12 |
| Sector | Health Care |
| Industries | |
Description
Kubota Pharmaceutical Holdings Co., Ltd. develops portfolio of drugs and devices worldwide. Its product pipeline comprises emixustat hydrochloride, which is in Phase III clinical stage used for the treatment of stargardt disease, and Phase II clinical stage used for the treatment of proliferative diabetic retinopathy. The company is also developing remote retinal monitoring device patient-based ophthalmology suite, that includes home-based miniature and NASA high-res version optical coherence tomography devices; and wearable device for myopia control. The company was founded in 2002 and is based in Tokyo, Japan.
Key trends
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email